Conjunctivitis Treatment Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global market value of the conjunctivitis treatment market was USD 4.9 billion in 2022, and a CAGR of 5.1% is expected during the forecast period. It is an inflammation of the membrane covering the eyeball, and the conjunctiva part of the eye is affected due to it in the rainy season. It is easily spread from one person to another, but it rarely affects the human eye negatively. Allergy-related conjunctivitis is highly common, and it mainly occurs in the season of hay fever. The conjunctivitis treatment market involves various approaches to managing this condition.

For bacterial conjunctivitis, antibiotic eye drops or ointments are commonly prescribed. If the conjunctivitis is viral, antiviral medications are used, though viral conjunctivitis often resolves on its own. Lubricating eye drops help alleviate symptoms and maintain eye moisture. In cases of allergic conjunctivitis, antihistamine eye drops are recommended for the patient. In severe cases, steroid eye drops are used to treat the patient.

Impact of Covid-19

The COVID-19 pandemic has had several impacts on the conjunctivitis treatment market. Lockdowns or restrictions led to reduced access to healthcare facilities, affecting the timely diagnosis and treatment of conjunctivitis. With a heightened focus on hygiene practices during the pandemic, there has been increased awareness about eye health, potentially driving demand for conjunctivitis treatment. Disruptions in the supply chain have impacted the availability of conjunctivitis medications on time, causing fluctuations in the market. The pandemic accelerated the adoption of telemedicine, allowing remote consultation for conjunctivitis cases and impacting the traditional distribution channels. The increased use of personal protective equipment like face masks has decreased the spread of conjunctivitis. The urgency to address various aspects of the pandemic has diverted resources and attention from certain non-pandemic-related research. Potentially impacting innovations in conjunctivitis treatment.

Growth Drivers

The conjunctivitis treatment market is growing due to changes in lifestyle and the increasing prevalence of allergic conjunctivitis. Investment in research and development for the advent of new medicines and therapies is also a big factor behind the growth of this market. The rising incidence of hemorrhagic conjunctivitis is driving the growth of the market. Increased awareness campaigns and partnerships with healthcare professionals are another factor driving the growth of the market. Increasing consciousness about eye-related issues is driving the growth of the market significantly.

Growth in research and development activities in order to get better treatment is driving the growth in the market significantly. Increased healthcare expenditure and technological advancements are driving the growth of the market. Increasing air pollution, globalization, and industrialization are driving the growth of the market significantly. The rising burden of bacterial conjunctivitis infection is another factor responsible for the growth.

Segmentation

Drug Class

·         Antibiotics

·         Antivirals

·         Antiallergic

·         Artificial Tears

Disease Type

·         Bacterial

·         Chemical

·         Viral

·         Allergic Conjunctivitis

Route of Administration

·         Oral

·         Topical

End-User

·         Hospital

·         Online Pharmacies

·         Retail Pharmacies

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Conjunctivitis Treatment Market Drug Class Segmentation

On the basis of drug class, the conjunctivitis treatment market is segmented into antibiotics, antivirals, antiallergics, and artificial tears. Antibiotics are the leading segment, and they play a crucial role in the conjunctivitis treatment market, targeting the bacterial infection that causes conjunctivitis. Common antibiotic eyedrops or ointments, such as fluoroquinolones or aminoglycosides, are prescribed to combat bacterial infection. Antivirals are used to treat viral infections, particularly in cases of viral conjunctivitis. These medicines are often in the form of eyedrops. Artificial tears are a common component in the conjunctivitis treatment market, providing lubrication and relief from dryness, irritation, or discomfort associated with the condition.

Conjunctivitis Treatment Market Disease Type Segmentation

On the basis of disease type, the conjunctivitis market is segmented into bacterial, chemical, viral, and allergic conjunctivitis. Bacterial and allergic conjunctivitis is the most common type, which is treated with the help of antibiotics or anti-allergic drops. Commonly prescribed antibiotics are fluoroquinolones and aminoglycosides. Proper use of these medications helps eliminate the bacteria and provides us with quick relief. Allergic conjunctivitis is managed through antihistamine or mast cell stabilizer eye drops. These medications help control the immune response triggered by allergens, reducing symptoms like itching, redness, and swelling. In severe cases, anti-inflammatory drugs are prescribed, but they are generally used for short durations due to their potential side effects.

Conjunctivitis Treatment Market End User Segmentation

On the basis of the end-user, the conjunctivitis treatment market is segmented into hospitals, online pharmacies, and retail pharmacies. Retail pharmacies are the leading segment and are expected to grow significantly during the forecast period. This is because many individuals with conjunctivitis seek over-the-counter remedies or prescription medications directly from the local retail pharmacies for convenience and immediate access. Online pharmacies are another segment that is expected to grow moderately during the forecast period.

Regional Outlook

On the basis of the regions, the conjunctivitis treatment market is segmented into 5 parts: Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. The North American market is expected to grow at the fastest rate during the forecast period due to the well-established healthcare infrastructure and high health care spending, which facilitate easy access to advanced treatments. Moreover, more research and development activities in the region, along with the large number of pharmaceutical companies, contribute to the continuous innovation of conjunctivitis treatments. The prevalence of allergies and environmental factors is driving the growth in the region.

The Asia-Pacific region, particularly India, is a very big market. This region is often influenced by environmental factors, and population density and varying healthcare standards are driving the growth in the market significantly. Rising awareness about eye health and access to healthcare services have improved, leading to early diagnosis and treatment. Due to a surge in research and development activities, government initiatives to collaborate with global healthcare organizations also contribute to the expansion of the conjunctivitis treatment market. The presence of key players in North America and the Asia-Pacific region is driving the growth of the market significantly.

Key Players

·         Novartis AG

·         Cipla Limited

·         Abbvie Inc

·         Dr. Reddy’s Laboratories limited

·         Micro Labs Limited

·         Ocular Therapeutix Inc

·         Akkorn operating company

·         Vitaris Inc

·         Aurobindo Pharma Limited

·         Other Players